Modernizing Central Monitoring in Clinical Trials

Discover how TRI is transforming clinical research through smarter, data-driven solutions.

Driving Smarter Clinical Trials with RBQM

RBQM is redefining how clinical trials are designed, enabling smarter, more resilient research.

Collaborating Under ICH E6 (R3)

Explore how sponsors and CROs must rethink collaboration and embed quality into every layer of trial execution.

Why ICH E6 R3 Matters for Clinical Trials

Explore how E6 (R3) reshapes trial design, oversight, and culture, and why the industry must be ready to respond.

What is ICH E6 (R3)?

ICH E6 (R3) sets a new global benchmark for Good Clinical Practice, modernizing oversight with principle-based, risk-driven, and digitally enabled trial design.

Lessons from London

This blog explores how clinical research leaders are navigating post-Covid uncertainty, shifting buyer expectations, and the growing need for authenticity, trust, and AI-driven value.

Dose Optimization in Oncology: Advancing Clinical Trial Quality

The FDA’s latest guidance on dose optimization marks a pivotal shift in oncology drug development.

New FDA Guidance Reshapes Decentralized Trial Oversight

The FDA’s new guidance on marks a pivotal shift in clinical research, promoting accessibility while emphasizing the need for enhanced risk oversight.